Stockreport

ALX Oncology Holdings Inc (ALXO) Q3 2025 Earnings Call Highlights: Promising Clinical Advances ... [Yahoo! Finance]

ALX Oncology Holdings Inc.  (ALXO) 
PDF Objective Response Rate (ORR): 41% in the evorpacept arm vs. 27% in the control arm for HER2-positive gastric patients. ORR in CD47 High Expression Patients: 65% in t [Read more]